Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)

Currently no specific biomarkers exist for the screening of pregnancies at risk for down syndrome (DS). Since a quantitative proteomic approach with isobaric labelling (iTRAQ) has recently been suggested to be highly suitable for the discovery of novel plasma biomarkers, we have now used this method...

Full description

Bibliographic Details
Main Authors: Varaprasad Kolla, Paul Jenö, Suzette Moes, Sevgi Tercanli, Olav Lapaire, Mahesh Choolani, Sinuhe Hahn
Format: Article
Language:English
Published: Hindawi Limited 2010-01-01
Series:Journal of Biomedicine and Biotechnology
Online Access:http://dx.doi.org/10.1155/2010/952047
id doaj-62ffcb8c750742c6a05e80a9bdbf9efa
record_format Article
spelling doaj-62ffcb8c750742c6a05e80a9bdbf9efa2020-11-25T02:03:38ZengHindawi LimitedJournal of Biomedicine and Biotechnology1110-72431110-72512010-01-01201010.1155/2010/952047952047Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)Varaprasad Kolla0Paul Jenö1Suzette Moes2Sevgi Tercanli3Olav Lapaire4Mahesh Choolani5Sinuhe Hahn6Department of Biomedicine, University Women’s Hospital, 4031 Basel, SwitzerlandMass Spectrometry, Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, SwitzerlandMass Spectrometry, Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel, SwitzerlandDepartment of Biomedicine, University Women’s Hospital, 4031 Basel, SwitzerlandDepartment of Biomedicine, University Women’s Hospital, 4031 Basel, SwitzerlandBiomarker Discovery Laboratory, Department of Obstetrics and Gynecology, National University of Singapore, 19077, SingaporeDepartment of Biomedicine, University Women’s Hospital, 4031 Basel, SwitzerlandCurrently no specific biomarkers exist for the screening of pregnancies at risk for down syndrome (DS). Since a quantitative proteomic approach with isobaric labelling (iTRAQ) has recently been suggested to be highly suitable for the discovery of novel plasma biomarkers, we have now used this method to examine for potential quantitative changes in the plasma proteome of the pregnancies bearing DS fetuses in comparison to normal healthy babies. In our study, we used plasma from six women with DS pregnancies and six with uncomplicated pregnancies care were taken to match cases and controls for gestational and maternal age, as these could be a confounder. In our quantitative proteomics analysis we were able to detect 178 proteins using iTRAQ labelling in conjunction with 4800 MALDI TOF/TOF. Amongst these we observed changes in βHCG, a known screening marker for DS, indicating that our assay was functional. We found a number of elevated proteins Ig lambda chain C region, serum amyloid P-component, amyloid beta A4, and under expressed proteins like gamma-actin and titin in DS pregnancies. These proteins are also found in the sera of patients with Alzheimer disease, which share similar pathologies of DS. Our study therefore indicates that the iTRAQ labelling approach may be indeed useful for the detection of novel biomarkers.http://dx.doi.org/10.1155/2010/952047
collection DOAJ
language English
format Article
sources DOAJ
author Varaprasad Kolla
Paul Jenö
Suzette Moes
Sevgi Tercanli
Olav Lapaire
Mahesh Choolani
Sinuhe Hahn
spellingShingle Varaprasad Kolla
Paul Jenö
Suzette Moes
Sevgi Tercanli
Olav Lapaire
Mahesh Choolani
Sinuhe Hahn
Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)
Journal of Biomedicine and Biotechnology
author_facet Varaprasad Kolla
Paul Jenö
Suzette Moes
Sevgi Tercanli
Olav Lapaire
Mahesh Choolani
Sinuhe Hahn
author_sort Varaprasad Kolla
title Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)
title_short Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)
title_full Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)
title_fullStr Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)
title_full_unstemmed Quantitative Proteomics Analysis of Maternal Plasma in Down Syndrome Pregnancies Using Isobaric Tagging Reagent (iTRAQ)
title_sort quantitative proteomics analysis of maternal plasma in down syndrome pregnancies using isobaric tagging reagent (itraq)
publisher Hindawi Limited
series Journal of Biomedicine and Biotechnology
issn 1110-7243
1110-7251
publishDate 2010-01-01
description Currently no specific biomarkers exist for the screening of pregnancies at risk for down syndrome (DS). Since a quantitative proteomic approach with isobaric labelling (iTRAQ) has recently been suggested to be highly suitable for the discovery of novel plasma biomarkers, we have now used this method to examine for potential quantitative changes in the plasma proteome of the pregnancies bearing DS fetuses in comparison to normal healthy babies. In our study, we used plasma from six women with DS pregnancies and six with uncomplicated pregnancies care were taken to match cases and controls for gestational and maternal age, as these could be a confounder. In our quantitative proteomics analysis we were able to detect 178 proteins using iTRAQ labelling in conjunction with 4800 MALDI TOF/TOF. Amongst these we observed changes in βHCG, a known screening marker for DS, indicating that our assay was functional. We found a number of elevated proteins Ig lambda chain C region, serum amyloid P-component, amyloid beta A4, and under expressed proteins like gamma-actin and titin in DS pregnancies. These proteins are also found in the sera of patients with Alzheimer disease, which share similar pathologies of DS. Our study therefore indicates that the iTRAQ labelling approach may be indeed useful for the detection of novel biomarkers.
url http://dx.doi.org/10.1155/2010/952047
work_keys_str_mv AT varaprasadkolla quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq
AT pauljeno quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq
AT suzettemoes quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq
AT sevgitercanli quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq
AT olavlapaire quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq
AT maheshchoolani quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq
AT sinuhehahn quantitativeproteomicsanalysisofmaternalplasmaindownsyndromepregnanciesusingisobarictaggingreagentitraq
_version_ 1724946836081344512